Genfit SA

Genfit SA (GNFT) Stock Analysis

$4.850

+0.123 (+2.54%)At close

Loading chart…
High
4.929
Open
4.380
VWAP
4.72
Vol
56.95K
Mkt Cap
192.46M
Low
4.372
Amount
268.63K
EV/EBITDA, TTM
61.82

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

www.genfit.fr

Valuation Metrics

The current forward P/E ratio for Genfit SA (GNFT) is -3.81, compared to its 5-year average forward P/E of 6.75.

Forward P/E

Fair
5Y Average P/E
6.75
Current P/E
-3.81
Overvalued
60.99
Undervalued
-47.50

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
2.10
Current EV/EBITDA
61.82
Overvalued
16.88
Undervalued
-12.68

Forward P/S

Fair
5Y Average P/S
3.90
Current P/S
1.63
Overvalued
6.46
Undervalued
1.35

GNFT FAQ — answered by Alphio AI

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making. It operates in the Healthcare sector.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started